ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines"

  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • Abstract Number: L06 • ACR Convergence 2024

    Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies

    Raphael Kirou1, Iago Pinal-Fernandez1 and Andrew Mammen2, 1NIAMS/National Institutes of Health, Bethesda, MD, 2NIH, Bethesda, MD

    Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
  • Abstract Number: L18 • ACR Convergence 2024

    CCL19+ Fibroblasts Orchestrate Fibrotic Microenvironment via CCL19-CCR7 Axis in Systemic Sclerosis

    Wei Guo1, Zhaohua Li2, Dan Xu2 and Rong Mu2, 1Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China, 2Peking University Third Hospital, Beijing, China

    Background/Purpose: Understanding the roles of diverse fibroblast subsets is of great importance in elucidating the pathogenesis of fibrosis in systemic sclerosis (SSc). However, how the…
  • Abstract Number: 0082 • ACR Convergence 2024

    Comparative Immunology of Entheseal Anchorage Sites Between Spine, Hip and Knee Demonstrates up to 70-fold Greater IL-23 Induction from Axial Enthesis Bone: A New Angle on the Failure of IL-23 Blockade in Ankylosing Spondylitis

    Mark Harland1, Paula David2, Chi Wong1, Jake Weddell1, Abhay Rao3, Almas Khan3, Jake Timothy3, Peter Loughenbury3, Robert Dunsmuir3, Vishal Borse3, Campbell MacEachern3, Antonius Pieter Van der Heuvel4, Warner Chen4, Tom Macleod1 and Dennis McGonagle5, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK, Leeds, United Kingdom, 2Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel, Ramat Gan, Israel, 3Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, USA, Spring House, PA, 5National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK, Leeds, England, United Kingdom

    Background/Purpose: Both peripheral and axial spondyloarthropathy (SpA), psoriasis and inflammatory bowel disease are strongly linked to IL-23 pathway immunogenetics and immunology. Unexpectedly, IL-23 inhibition lacked…
  • Abstract Number: 0883 • ACR Convergence 2024

    The Study of 62 Circulating Soluble Factors Is Able to Predict the Lack of Response to MTX Treatment in Recently Diagnosed DMARD Naïve Rheumatoid Arthritis Smoker and Non-Smoker Patients

    Jorge Monserrat1, Cristina Bohorquez2, Ana Maria Gómez3, Elena Rabadán Rubio4, Raquel Sánchez3, Atusa Movasat5, Lucia Ruiz4, Fernando Albarran Hernandez6, Miguel Ángel Ortega1, Ana Perez6 and Melchor Alvarez-Mon7, 1Universidad de Alcalá. IRYCIS, Alcalá de Henares, Madrid, Spain, 2Hospital Universitario Príncipe de Asturias, Alcalá De Henares, Madrid, Spain, 3Universidad de Alcalá, Alcalá de Henares, Madrid, Spain, 4Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, 5Hospital Universitario Príncipe de Asturias, Madrid, Spain, 6Hospital Universitario Principe de Asturias, Alcala de Henares, Madrid, Spain, 7Universidad de Alcalá. HUPA. IRYCIS, Madrid, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is a highly inflammatory severe chronic autoimmune disorder with an inadequate activation of the immune cells. These cells are responsible for…
  • Abstract Number: 1701 • ACR Convergence 2024

    STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity

    Hyun Hee Kim1, Haochen Jiang2, Tatiana Ort3, Gary Sims3 and Richard Hanna4, 1AstraZeneca, Gaithersburg, MD, 2University of Nebraska, Omaha, NE, 3Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4AstraZeneca, Dickerson, MD

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
  • Abstract Number: 2616 • ACR Convergence 2024

    Associations of Circulating Inflammatory Cytokines with Long COVID Among Patients with Systemic Autoimmune Rheumatic Diseases

    Jeffrey Sparks1, Xiaosong Wang2, Pui Lee3, Kailey Brodeur4, Miao Lin5, Naomi Patel5, Yumeko Kawano6, Abigail Schiff7, Andrew King5, Jennifer Hanberg6, Shruthi Srivatsan5, Emily Kowalski6, Colebrook Johnson5, Kathleen Vanni6, Zachary Williams5, Grace Qian2, Caleb Bolden5, Kevin Mueller6, Katarina Bade6, Alene Saavedra6, Rathnam Venkat8 and Zachary Wallace9, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Boston Children's Hospital, Newton, MA, 4Boston Children's Hospital, Cumberland, RI, 5Massachusetts General Hospital, Boston, MA, 6Brigham and Women's Hospital, Boston, MA, 7Brigham and Women's Hospital, Cambridge, MA, 8Tufts University School of Medicine, Boston, MA, 9Massachusetts General Hospital, Newton, MA

    Background/Purpose: While the incidence of severe acute COVID-19 has decreased, post-acute sequelae of COVID-19 characterized by prolonged symptoms, or ‘long COVID,’ is common and associated…
  • Abstract Number: 0090 • ACR Convergence 2024

    Parenchymal and Hematopoietic IFNγ Signaling Exhibits Dichotomous Effects in Murine Lupus

    Minjung Kim1, Anthony Marinov2, Haylee Cosgrove3, Xiaoyan Gong3, Mark Shlomchik3 and Jeremy Tilstra3, 1University of Illinois College of Medicine at Chicago, Chicago, IL, 2University of Pittsburgh, Homestead, PA, 3University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Lupus nephritis is the most common life-threatening end-organ complication of SLE, and response rates to current interventions remain poor. Notably, PD-L1 and other interferon-responsive…
  • Abstract Number: 0922 • ACR Convergence 2024

    Generation and Pathophysiological Analysis of M694I Variant Knock-in Mice of Human MEFV Gene: Insights from Single-Cell RNA Sequencing

    Tomohiro Koga, Yoshika Tsuji and Atsushi Kawakami, Nagasaki University, Nagasaki, Japan

    Background/Purpose: The primary objective of this study was to generate knock-in mice with the M694I variant of the human MEFV gene, a critical variant in…
  • Abstract Number: 1704 • ACR Convergence 2024

    Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis

    Dimitrios Anastasios Palamidas1, Maria Papadaki2, Nikolaos Paschalidis3, Eleftherios Pavlos4, Loukas chatzis1, Ourania Argyropoulou5, Panagiota Palla5, Ioanna-Evdokia Galani6, Andreas Goules7, Evangelos Andreakos4 and Athanasios Tzioufas8, 1Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, 2Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, 3Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, 4Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, 5Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, 6Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, 7GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, 8LAIKO HOSPITAL, Athens, Greece

    Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: 0246 • ACR Convergence 2024

    Selectively Targeting TRBV11-2+ T Cells in Multisystem Inflammatory Syndrome in Children (MIS-C) Using Bispecific T Cell-Engaging Antibodies

    Elana Shaw, Stephanie Glavaris, Brian Mog, Alexander Pearlman, Sarah DiNapoli, Jin Liu, Kyle J. Kaeo, Kenneth W. Kinzler, Chetan Bettegowda, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a rare but potentially deadly immune complication after infection with SARS-CoV-2. In patients with MIS-C, a striking…
  • Abstract Number: 0934 • ACR Convergence 2024

    Screening NLRP3 Drug Candidates in Clinical Development:Lessons from Existing and Emerging Technologies

    Isak Tengesdal1, Carlo Marchetti1, Tim L.Th. Jansen2, Marc Y. Donath3, Naomi Schlesinger4 and Charles Dinarello1, 1University of Colorado, Denver, CO, 21VieCuri Medisch Centrum, Venlo, Netherlands, 3University of Basel, Basel, Switzerland, 4University of Utah, Salt Lake City, UT

    Background/Purpose: NLRP3 is emerging as an attractive upstream target of the pathway to down-modulate rather than to completely neutralize IL-1ß levels in both acute and…
  • Abstract Number: 1765 • ACR Convergence 2024

    CD8+ T Cells and Monocytes from Children with Macrophage Activation Syndrome Demonstrate Specific Transcriptional Changes Consistent with T Cell Activation and Expansion of Monocytes Shaped by Interferon and TLR Signaling

    Susan Canny1, Hannah DeBerg2, Griffin Gessay2, Ailing Lu3, Mary Eckert4, Andrea La Bella5, Hayley Waterman2, Danish Nadeem2, Susan Shenoi6, Joyce Hui-Yuen7, Daniel Campbell2, Betsy Barnes8 and Jessica Hamerman2, 1University of Washington, Seattle, WA, 2Benaroya Research Institute, Seattle, WA, 3Northwell Health, Manhasset, NY, 4Seattle Children's Hospital, Seattle, WA, 5Cohen Children's Medical Center, Queens, NY, 6Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, 7North Shore LIJ Health System, Great Neck, NY, 8Feinstein Institutes for Medical Science, Manhasset, NY

    Background/Purpose: Macrophage activation syndrome (MAS), a form of secondary hemophagocytic lymphohistiocytosis (sHLH), is a potentially fatal complication of rheumatic diseases. MAS is characterized by a…
  • Abstract Number: 0275 • ACR Convergence 2024

    Targeting IRAK4 in Monosodium Urate Crystals Induced Inflammation

    Sadiq Umar1 and Sriram Ravindran2, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois, Chicago

    Background/Purpose: Gout, the leading cause of inflammatory arthritis, is becoming increasingly prevalent worldwide, affecting both developed and developing countries. This condition results from the deposition…
  • 1
  • 2
  • 3
  • …
  • 38
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology